Literature DB >> 8006593

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

P G Coulie1, V Brichard, A Van Pel, T Wölfel, J Schneider, C Traversari, S Mattei, E De Plaen, C Lurquin, J P Szikora, J C Renauld, T Boon.   

Abstract

It has been reported previously that antitumor cytolytic T lymphocyte (CTL) clones can be isolated from blood lymphocytes of HLA-A2 melanoma patients, after stimulation in vitro with autologous tumor cells, and that some of these CTL clones lyse most HLA-A2 melanomas. A first antigen recognized by such CTL clones was previously shown to be encoded by the tyrosinase gene. We report here the identification of another gene that also directs the expression of an antigen recognized on most melanomas by CTL clones that are restricted by HLA-A2. The gene, designated Melan-A, is unrelated to any known gene. It is 18 kb long and comprises five exons. Like the tyrosinase gene, it is expressed in most melanoma tumor samples and, among normal cells, only in melanocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006593      PMCID: PMC2191574          DOI: 10.1084/jem.180.1.35

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

Authors:  A Knuth; T Wölfel; E Klehmann; T Boon; K H Meyer zum Büschenfelde
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  Identification of DNA sequences required for transcription of the human alpha 1-globin gene in a new SV40 host-vector system.

Authors:  P Mellon; V Parker; Y Gluzman; T Maniatis
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

3.  Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma.

Authors:  T L Darrow; C L Slingluff; H F Seigler
Journal:  Cancer       Date:  1988-07-01       Impact factor: 6.860

4.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.

Authors:  A Knuth; B Danowski; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

5.  Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes.

Authors:  C Traversari; P van der Bruggen; B Van den Eynde; P Hainaut; C Lemoine; N Ohta; L Old; T Boon
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

6.  A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum.

Authors:  M J Mattes; T M Thomson; L J Old; K O Lloyd
Journal:  Int J Cancer       Date:  1983-12-15       Impact factor: 7.396

7.  Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Authors:  M Hérin; C Lemoine; P Weynants; F Vessière; A Van Pel; A Knuth; R Devos; T Boon
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

8.  Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

Authors:  E De Plaen; C Lurquin; A Van Pel; B Mariamé; J P Szikora; T Wölfel; C Sibille; P Chomez; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

9.  Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.

Authors:  B Seed; A Aruffo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

10.  Clonal analysis of cytotoxic T cell response against human melanoma.

Authors:  B Mukherji; T J MacAlister
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

View more
  172 in total

1.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

2.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

3.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

4.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors:  E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

5.  Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles.

Authors:  S Chaudhuri; A Cariappa; M Tang; D Bell; D A Haber; K J Isselbacher; D Finkelstein; D Forcione; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

6.  In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.

Authors:  Christoph Esslinger; Laurence Chapatte; Daniela Finke; Isabelle Miconnet; Philippe Guillaume; Frédéric Lévy; H Robson MacDonald
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 7.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

Review 8.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

9.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

10.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Authors:  Fan Huang; Christophe Gonçalves; Margarita Bartish; Joelle Rémy-Sarrazin; Mark E Issa; Brendan Cordeiro; Qianyu Guo; Audrey Emond; Mikhael Attias; William Yang; Dany Plourde; Jie Su; Marina Godoy Gimeno; Yao Zhan; Alba Galán; Tomasz Rzymski; Milena Mazan; Magdalena Masiejczyk; Jacek Faber; Elie Khoury; Alexandre Benoit; Natascha Gagnon; David Dankort; Fabrice Journe; Ghanem E Ghanem; Connie M Krawczyk; H Uri Saragovi; Ciriaco A Piccirillo; Nahum Sonenberg; Ivan Topisirovic; Christopher E Rudd; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.